廣南(集團)(01203.HK)一季度淨利1877.5萬港元 同比減少9.3%
格隆匯4月28日丨廣南(集團)(01203.HK)公吿,2022年第一季度,公司及其附屬公司(統稱"集團")未經審核綜合收入為14.12億港元,較去年同期增加76.3%,未經審核經營溢利為4498.4萬港元,較去年同期增加118.4%,增加主要來自馬口鐵業務較佳的表現,以及屠宰業務利潤上升的貢獻。但聯營公司因國內生豬銷售價格下降影響致利潤下跌,故本期未經審核綜合股東應占溢利為1877.5萬港元,較去年同期減少9.3%。集團的計劃是在半年度及年度結束時考慮宣派股息,故2022年第一季度不建議派發任何股息(2021年第一季度:零港元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.